Jamie M Jacobs1,2, Molly E Ream1, Nicole Pensak3, Lauren E Nisotel4, Joel N Fishbein5, James J MacDonald6, Joanne Buzaglo7, Inga T Lennes1,2, Steven A Safren8, William F Pirl9, Jennifer S Temel1,2, Joseph A Greer1,2. 1. Massachusetts General Hospital Cancer Center, and. 2. Harvard Medical School, Boston, Massachusetts. 3. Anschutz Medical Campus, University of Colorado, Denver, Colorado. 4. Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 5. University of Colorado at Boulder, Boulder, Colorado. 6. University of California, Los Angeles, Los Angeles, California. 7. Cancer Support Community, Washington, DC. 8. University of Miami, Miami, Florida; and. 9. Dana-Farber Cancer Institute, Boston, Massachusetts.
Abstract
BACKGROUND: Oral therapies are increasingly common in oncology care. However, data are lacking regarding the physical and psychologic symptoms patients experience, or how these factors relate to medication adherence and quality of life (QoL). MATERIALS AND METHODS: From December 2014 through August 2016, a total of 181 adult patients who were prescribed oral targeted therapy or chemotherapy enrolled in a randomized study of adherence and symptom management at Massachusetts General Hospital Cancer Center. Patients completed baseline assessments of adherence with electronic pill cap, QoL, symptom severity, mood, social support, fatigue, and satisfaction with clinicians and treatment. Relationships among these factors were examined using Pearson product-moment correlations and multivariable linear regression. RESULTS: At baseline, the mean electronic pill cap adherence rate showed that patients took 85.57% of their oral therapy. The most commonly reported cancer-related symptoms were fatigue (88.60%), drowsiness (76.50%), disturbed sleep (68.20%), memory problems (63.10%), and emotional distress (60.80%). Patients who reported greater cancer-related symptom severity had lower adherence (r= -0.20). In a multivariable regression, greater depressive and anxiety symptoms, worse fatigue, less social support, lower satisfaction with clinicians and treatment, and higher symptom burden were associated with worse QoL (F[10, 146]=50.53; adjusted R2=0.77). Anxiety symptoms were most strongly associated with clinically meaningful decrements in QoL (β= -7.10; SE=0.22). CONCLUSIONS: Patients prescribed oral therapies struggle with adherence, and cancer-related symptom burden is high and related to worse adherence and QoL. Given perceptions that oral therapies are less impairing, these data underscore the strong need to address adherence issues, symptom burden, and QoL for these patients.
BACKGROUND: Oral therapies are increasingly common in oncology care. However, data are lacking regarding the physical and psychologic symptoms patients experience, or how these factors relate to medication adherence and quality of life (QoL). MATERIALS AND METHODS: From December 2014 through August 2016, a total of 181 adult patients who were prescribed oral targeted therapy or chemotherapy enrolled in a randomized study of adherence and symptom management at Massachusetts General Hospital Cancer Center. Patients completed baseline assessments of adherence with electronic pill cap, QoL, symptom severity, mood, social support, fatigue, and satisfaction with clinicians and treatment. Relationships among these factors were examined using Pearson product-moment correlations and multivariable linear regression. RESULTS: At baseline, the mean electronic pill cap adherence rate showed that patients took 85.57% of their oral therapy. The most commonly reported cancer-related symptoms were fatigue (88.60%), drowsiness (76.50%), disturbed sleep (68.20%), memory problems (63.10%), and emotional distress (60.80%). Patients who reported greater cancer-related symptom severity had lower adherence (r= -0.20). In a multivariable regression, greater depressive and anxiety symptoms, worse fatigue, less social support, lower satisfaction with clinicians and treatment, and higher symptom burden were associated with worse QoL (F[10, 146]=50.53; adjusted R2=0.77). Anxiety symptoms were most strongly associated with clinically meaningful decrements in QoL (β= -7.10; SE=0.22). CONCLUSIONS: Patients prescribed oral therapies struggle with adherence, and cancer-related symptom burden is high and related to worse adherence and QoL. Given perceptions that oral therapies are less impairing, these data underscore the strong need to address adherence issues, symptom burden, and QoL for these patients.
Authors: Kapeena Sivakumaran; Pamela K Ginex; Haya Waseem; Sarah M Belcher; Sarah Lagler-Clark; Kristine B LeFebvre; Nicole Palmer; Tejanth Pasumarthi; Rebecca L Morgan Journal: Oncol Nurs Forum Date: 2022-06-17 Impact factor: 1.803
Authors: Gwen Wyatt; Rebecca Lehto; Pratim Guha-Niyogi; Sarah Brewer; David Victorson; Thaddeus Pace; Terry Badger; Alla Sikorskii Journal: Res Nurs Health Date: 2021-07-19 Impact factor: 2.238
Authors: Marco Di Nitto; Fabio Sollazzo; Valentina Biagioli; Gianluca Pucciarelli; Francesco Torino; Rosaria Alvaro; Ercole Vellone Journal: Support Care Cancer Date: 2022-05-31 Impact factor: 3.359
Authors: Molly E Ream; Mollie S Pester; Zachary T Goodman; Sierra A Bainter; Michael H Antoni Journal: Psychooncology Date: 2020-12-21 Impact factor: 3.894
Authors: Laura B Oswald; Kelly A Hyland; Sarah L Eisel; Aasha I Hoogland; Hans Knoop; Ashley M Nelson; Javier Pinilla-Ibarz; Kendra Sweet; Paul B Jacobsen; Heather S L Jim Journal: Support Care Cancer Date: 2021-07-07 Impact factor: 3.359
Authors: Laura B Oswald; Brandy Arredondo; Mika Kadono; Dinorah Martinez-Tyson; Cathy D Meade; Frank Penedo; Michael H Antoni; Hatem Soliman; Ricardo L B Costa; Heather S L Jim Journal: Cancer Med Date: 2021-06-24 Impact factor: 4.452